Lindus Health raises $55M to expedite the clinical trial process

The clinical trial industry, a critical component of medical research and drug development, has long been plagued by inefficiencies, high costs, and protracted timelines. Traditional contract research organizations (CROs) often struggle with delays and budget overruns, hindering the timely delivery of new treatments to patients. Lindus Health, a London-based startup established in 2021, is poised to disrupt this paradigm by introducing a technology-driven approach to clinical trials. The company’s recent $55 million Series B funding round underscores its commitment to revolutionizing the industry through artificial intelligence (AI) and automation.

Company Overview

Lindus Health was founded with the mission to expedite the clinical trial process, making it more efficient and cost-effective. By integrating AI into trial management, the company seeks to automate labor-intensive tasks, thereby reducing human error and accelerating timelines. This approach not only enhances the reliability of trial outcomes but also significantly lowers operational costs, benefiting both researchers and patients.

Read also: Eleos Health Secures $60M to Transform Behavioral Healthcare

Funding Details

The $55 million Series B funding round was led by Balderton Capital, a prominent venture firm with a history of supporting innovative technology companies. Additional participation came from Creandum, Firstminute, Seedcamp, and Visionaries Club, reflecting strong investor confidence in Lindus Health’s vision and technological capabilities. 

This infusion of capital is earmarked for the further development of Lindus Health’s proprietary AI technology and eClinical platform, Citrus™, which is designed to optimize study design, automate central monitoring of study data, and enable instant biostatistics. PR NEWSWIRE

The Problem with Traditional CROs

Traditional CROs have been criticized for their inefficiency and high costs. Approximately 85% of clinical trials experience delays, often due to outdated methodologies and a lack of technological integration. These delays not only inflate research costs but also postpone the availability of potentially life-saving treatments. The conventional CRO model has remained largely unchanged for decades, creating a bottleneck in the advancement of medical research.

Lindus Health’s Innovative Approach

Lindus Health claims to be the “anti-CRO,” providing an integrated service with in-house technology for conducting clinical trials.

Citrus™ is the proprietary platform of the firm, based on the capabilities of AI to generate support in automating most aspects of a clinical trial, such as protocol design and data monitoring. Citrus can predict clinical trial results by analyzing historical data to devise more efficient study designs and derive outcomes with greater predictability. 

This technological integration enables Lindus Health to conduct trials up to three times faster than traditional CROs, providing high-quality data and reducing costs. 

Since its inception, Lindus Health has conducted 42 end-to-end clinical trials across diverse therapeutic areas, including psychiatry, diagnostics, and respiratory health.

The company has successfully enrolled over 36,000 patients in trials across North America and Europe.

Notable collaborations include a 7,500-patient device study with Aktiia and a Phase IV trial for insomnia with Pharmanovia. These achievements demonstrate Lindus Health’s capacity to manage large-scale studies efficiently, delivering reliable data that accelerates the development of new treatments. 

Strategic Advisory Board 

The strategic advisory board guiding the firm comprises such persons as Robert S. Langer, the co-founder of Moderna and over 40 other biotech companies, as well as a former Chief Medical Officer at Eli Lilly in the person of Tim Garnett, providing it an opportunity to develop expertise regarding clinical studies complexity in light of Lindus Health’s plan to transform this industry.

With the new funding, Lindus Health plans to enhance its AI capabilities and expand its operations.
The company intends to relocate its headquarters to the United States, reflecting its commitment to serving a global market.

Additionally, Lindus Health aims to invest in its commercial team and integrate with third-party tools, such as electronic medical records, to streamline data collection and analysis.

By advancing its AI applications, the company seeks to provide real-time data analysis, further improving the efficiency and reliability of clinical trials. 

Summary

 London-based startup Lindus Health, which was founded in 2021, has raised $55 million in a Series B funding round led by Balderton Capital, Creandum, Firstminute, Seedcamp, and Visionaries Club. The company plans to revolutionize the clinical trial industry through the use of artificial intelligence to streamline and accelerate the process of clinical trials, thereby eradicating inefficiencies and high costs associated with traditional contract research organizations.